STAAR/$STAA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About STAAR
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
- Ticker
- $STAA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 921
- Headquarters
- Lake Forest, United States
- Website
- www.staar.com
STAAR Metrics
BasicAdvanced
$1.2B
319.04
$0.08
1.23
-
Price and volume
Market cap
$1.2B
Beta
1.23
52-week high
$35.87
52-week low
$15.59
Average daily volume
679K
Financial strength
Current ratio
4.665
Quick ratio
3.863
Long term debt to equity
0.081
Total debt to equity
0.098
Profitability
EBITDA (TTM)
49.764
Gross margin (TTM)
76.62%
Net profit margin (TTM)
1.13%
Operating margin (TTM)
12.15%
Effective tax rate (TTM)
77.91%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.65%
Return on equity (TTM)
1.09%
Valuation
Price to earnings (TTM)
319.037
Price to revenue (TTM)
3.607
Price to book
3.37
Price to tangible book (TTM)
3.7
Price to free cash flow (TTM)
-181.474
Free cash flow yield (TTM)
-0.55%
Free cash flow per share (TTM)
-0.135
Growth
Revenue change (TTM)
51.30%
Earnings per share change (TTM)
-103.98%
3-year revenue growth (CAGR)
3.54%
10-year revenue growth (CAGR)
15.58%
3-year earnings per share growth (CAGR)
-47.12%
10-year earnings per share growth (CAGR)
-13.38%
What the Analysts think about STAAR
Analyst ratings (Buy, Hold, Sell) for STAAR stock.
Analyst projections of the future price of STAAR stock.
Bulls say / Bears say
STAAR returned to profit in Q2, earning $8.1 million after a $16.8 million loss a year earlier; gross margin edged up and cash rose to $181.5 million. That gives the recovery more financial support than sales growth alone. (STAAR Surgical)
EVO+ adoption and a richer mix of higher-priced toric lenses helped China sales rise 10% sequentially to $52.3 million. Management reported no excess distributor or hospital inventory, which supports the case that recent sales reflect procedure demand rather than channel restocking. (STAAR Surgical)
The US business has been growing, and FDA approval now covers patients aged 21–60, widening the potential customer pool. STAAR also reported first-quarter US sales growth of 22%, offering a growth avenue beyond China. (STAAR Surgical)
China accounted for more than half of Q2 sales, and two Chinese distributors represented a large share of receivables, creating significant exposure to a small number of customers and one market. A slowdown or disruption there could quickly affect results and collections. (STAAR Surgical, Seeking Alpha)
The 111% Q2 sales jump flatters the underlying trend: shipments to China had been minimal in the year-earlier quarter while distributors cleared excess stock, and sales outside China grew only 6%. This makes the headline growth rate a weak guide to the pace of broad-based demand. (STAAR Surgical)
Tariffs on US-made lenses shipped to China continue to weigh on gross margin, while the company also cited higher unit costs from previously low Swiss production volumes. Tariff relief depends on shifting all China-bound production to Switzerland, which STAAR expects by the end of 2026. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
STAAR Financial Performance
Revenues and expenses
STAAR Earnings Performance
Company profitability
Upcoming events
No upcoming events
STAAR News
AllArticlesVideos
STAAR Surgical Names Andrew Pilon as Vice President of Business Development
Business Wire3 weeks ago
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
Business Wire2 months ago
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
Business Wire2 months ago
Funds containing STAAR
Fund name | Fund size | $STAA weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.08% |
iShares Ageing Population£AGES | $953M | 0.08% |
iShares Ageing Population€AGED | $903M | 0.08% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.04% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.